Background Convincing data on epidermal growth factor receptor (EGFR) mutations in
Chinese patients with non-small-cell lung cancer (NSCLC) remain limited. We investigated …

Background: The aim of the study was to evaluate the efficacy of gefitinib and the epidermal
growth factor receptor (EGFR) mutation to gefitinib response in a series of Chinese patients …

Background Only a few randomized trials directly compared the relative efficacy of tyrosine
kinase inhibitors (TKIs) in patients with advanced epidermal growth factor receptor (EGFR) …

Background/Aim: A phase II trial was conducted to assess the efficacy and safety of gefitinib
plus bevacizumab for EGFR mutation-positive non-small cell lung cancer (NSCLC). Patients …

Gefitinib is effective in treating advanced non-small cell lung cancer (NSCLC), especially in
Asian patients in whom the prevalence of epidermal growth factor receptor (EGFR) mutation …

Since the first description of non-small cell lung cancer (NSCLC) with activating epidermal
growth factor receptor (EGFR) mutation as a distinct clinical entity, studies have proved …

Purpose We examined the impact of different epidermal growth factor receptor (EGFR)
mutations and clinical characteristics on progression-free survival (PFS) in patients with …

7521 Background: WJTOG3405 met its primary endpoint of progression free survival
(PFS)(9.2 months (mo.) for G vs. 6.3 mo. for CD, hazard ratio (HR) 0.489, 95% confidence …

Purpose Patients with advanced non-small cell lung cancer (NSCLC) harboring a sensitive
epidermal growth factor receptor (EGFR) mutation have been shown to exhibit a marked …

Aim: Most patients (pts) with EGFR mutation-positive NSCLC respond to 1st-line EGFR
tyrosine kinase inhibitors, but later acquire resistance. The Phase III, double-blind IRESSA …